David C Dale1. 1. Department of Medicine, University of Washington, Seattle, Washington, USA.
Abstract
PURPOSE OF REVIEW: Neutropenia absolute neutrophil count (ANC) less than 1.5 × 10(9)/l is a common hematological finding, and severe neutropenia, that is, ANC less than 0.5 × 10(9)/l is a well known risk factor for susceptibility to bacterial infections. This review provides a succinct clinical approach to the diagnosis and treatment of neutropenia with specific recommendations on the treatment of severe chronic neutropenia with the myeloid growth factor, granulocyte colony-stimulating factor (G-CSF). RECENT FINDINGS: Experts agree that patients with acute febrile neutropenia should be treated with antibiotics and that patients at high risk of severe neutropenia (>20% risk) after myelosuppressive chemotherapy should be treated prophylactically with a myeloid growth factor, usually G-CSF. The diversity of causes and consequences of chronic neutropenia make the diagnosis and management of these patients more complicated. SUMMARY: The review provides a stepwise approach to neutropenia focusing first on reaching a provisional diagnosis and treatment plan then steps to a final diagnosis. It also provides specific recommendations on the treatment of severe chronic neutropenia with G-CSF.
PURPOSE OF REVIEW: Neutropenia absolute neutrophil count (ANC) less than 1.5 × 10(9)/l is a common hematological finding, and severe neutropenia, that is, ANC less than 0.5 × 10(9)/l is a well known risk factor for susceptibility to bacterial infections. This review provides a succinct clinical approach to the diagnosis and treatment of neutropenia with specific recommendations on the treatment of severe chronic neutropenia with the myeloid growth factor, granulocyte colony-stimulating factor (G-CSF). RECENT FINDINGS: Experts agree that patients with acute febrile neutropenia should be treated with antibiotics and that patients at high risk of severe neutropenia (>20% risk) after myelosuppressive chemotherapy should be treated prophylactically with a myeloid growth factor, usually G-CSF. The diversity of causes and consequences of chronic neutropenia make the diagnosis and management of these patients more complicated. SUMMARY: The review provides a stepwise approach to neutropenia focusing first on reaching a provisional diagnosis and treatment plan then steps to a final diagnosis. It also provides specific recommendations on the treatment of severe chronic neutropenia with G-CSF.
Authors: Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova Journal: Haematologica Date: 2013-12 Impact factor: 9.941
Authors: D C Dale; M A Bonilla; M W Davis; A M Nakanishi; W P Hammond; J Kurtzberg; W Wang; A Jakubowski; E Winton; P Lalezari Journal: Blood Date: 1993-05-15 Impact factor: 22.113
Authors: David C Dale; Audrey Anna Bolyard; Beate G Schwinzer; Gusal Pracht; Mary Ann Bonilla; Laurence Boxer; Melvin H Freedman; Jean Donadieu; George Kannourakis; Blanche P Alter; Bonnie P Cham; Jerry Winkelstein; Sally E Kinsey; Cornelia Zeidler; Karl Welte Journal: Support Cancer Ther Date: 2006-07-01
Authors: Michael W Curtis; Beth L Hahn; Kai Zhang; Chunhao Li; Richard T Robinson; Jenifer Coburn Journal: Infect Immun Date: 2018-01-22 Impact factor: 3.441
Authors: Helen A Papadaki; Irene Mavroudi; Antonio Almeida; Juergen Bux; Joanna Cichy; David C Dale; Jean Donadieu; Petter Höglund; Oliver Karanfilski; Cristina Mecucci; Jan Palmblad; Julia Skokowa; Kostas Stamatopoulos; Ivo Touw; Alan J Warren; Karl Welte; Cornelia Zeidler; Carlo Dufour Journal: Hemasphere Date: 2020-06-08